The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

D. Coward Biography and Net Worth

Insider of Exact Sciences

Scott Coward has served as our Senior Vice President, General Counsel, Chief Administrative Officer and Secretary since 2015 and as our Chief Administrative Officer since July 2018. Prior to joining Exact Sciences, Mr. Coward served as Managing Partner of the Raleigh, North Carolina office of K&L Gates LLP, General Counsel at Blue Rhino Corporation, Associate General Counsel at GE Medical Systems, and Partner at Smith Anderson. Mr. Coward holds a bachelor’s degree from the University of North Carolina, Chapel Hill and earned his Juris Doctorate from Columbia Law School.

What is D. Scott Coward's net worth?: The estimated net worth of D. Scott Coward is at least $2.51 million as of May 1st, 2024. Mr. Coward owns 44,644 shares of Exact Sciences stock worth more than $2,509,439 as of December 30th. This net worth approximation does not reflect any other assets that Mr. Coward may own. Learn More about D. Scott Coward's net worth.
How do I contact D. Scott Coward?: The corporate mailing address for Mr. Coward and other Exact Sciences executives is 5505 ENDEAVOR LANE, MADISON WI, 53719. Exact Sciences can also be reached via phone at (608) 284-5700 and via email at [email protected]. Learn More on D. Scott Coward's contact information.
Has D. Scott Coward been buying or selling shares of Exact Sciences?: D. Scott Coward has not been actively trading shares of Exact Sciences over the course of the past ninety days. Most recently, D Scott Coward sold 67 shares of the business's stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a transaction totalling $4,030.05. Following the completion of the sale, the director now directly owns 44,644 shares of the company's stock, valued at $2,685,336.60. Learn More on D. Scott Coward's trading history.
Who are Exact Sciences' active insiders?: Exact Sciences' insider roster includes Brian Baranick (Insider), Sarah Condella (SVP), Kevin Conroy (CEO), D. Coward (Insider), Everett Cunningham (Insider), James Doyle (Director), Jeffrey Elliott (CFO), James Herriott (General Counsel), Torsten Hoof (Insider), Daniel Levangie (Director), Graham Lidgard (Insider), Jacob Orville (Insider), and Katherine Zanotti (Director). Learn More on Exact Sciences' active insiders.
Are insiders buying or selling shares of Exact Sciences?: In the last twelve months, Exact Sciences insiders bought shares 1 times. They purchased a total of 19,500 shares worth more than $1,001,325.00. In the last twelve months, insiders at the medical research company sold shares 35 times. They sold a total of 75,348 shares worth more than $4,597,043.93. The most recent insider tranaction occured on November, 13th when CEO Kevin T Conroy bought 19,500 shares worth more than $1,001,325.00. Insiders at Exact Sciences own 1.4% of the company. Learn More about insider trades at Exact Sciences.
Information on this page was last updated on 11/13/2024.

D. Scott Coward Insider Trading History at Exact Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/1/2024	Sell	67	$60.15	$4,030.05	44,644
2/21/2024	Sell	706	$61.50	$43,419.00	43,122
2/15/2024	Sell	1,376	$61.43	$84,527.68	41,580
2/28/2023	Sell	4,153	$61.12	$253,831.36	32,775
2/15/2023	Sell	1,821	$65.59	$119,439.39	26,493
3/1/2022	Sell	3,912	$76.69	$300,011.28
2/24/2022	Sell	5,815	$70.10	$407,631.50
1/3/2019	Sell	1,581	$62.75	$99,207.75	80,544
10/1/2018	Sell	2,190	$79.51	$174,126.90
7/2/2018	Sell	2,135	$59.10	$126,178.50
4/2/2018	Sell	2,122	$40.12	$85,134.64
3/12/2018	Sell	2,708	$52.19	$141,330.52
2/26/2018	Sell	4,420	$42.34	$187,142.80
1/3/2018	Sell	1,665	$52.54	$87,479.10	37,558
10/2/2017	Sell	29,115	$47.16	$1,373,063.40	64,991
7/3/2017	Sell	1,987	$35.21	$69,962.27	57,603
4/3/2017	Sell	1,543	$23.74	$36,630.82	55,478
3/13/2017	Sell	1,983	$21.16	$41,960.28	50,790
2/27/2017	Sell	7,046	$21.48	$151,348.08	53,794
1/3/2017	Sell	1,535	$13.61	$20,891.35	29,242
4/1/2016	Sell	1,685	$6.62	$11,154.70	21,014
3/10/2016	Sell	2,175	$6.05	$13,158.75	18,501

D. Scott Coward Buying and Selling Activity at Exact Sciences

Exact Sciences Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Today's Range

Now: $56.21

$55.61

$57.23

50 Day Range

MA: $60.43

$49.33

$71.51

2 Week Range

Now: $56.21

$40.62

$79.62

Volume

317,494 shs

Average Volume

2,578,630 shs

Market Capitalization

$10.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.